Recent News

• 03.31.2026 - Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
• 03.26.2026 - Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
• 03.23.2026 - Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
• 03.23.2026 - Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
• 03.18.2026 - Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
• 03.18.2026 - Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
• 03.17.2026 - Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
• 03.17.2026 - Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
• 03.12.2026 - Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
• 03.12.2026 - Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Recent Filings

• 03.30.2026 - DEF 14A Other definitive proxy statements
• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.26.2026 - 8-K Current report
• 03.20.2026 - PRE 14A Other preliminary proxy statements
• 03.18.2026 - 8-K Current report
• 03.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2026 - ARS Annual Report to Security Holders
• 03.13.2026 - 8-K Current report
• 03.12.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]